Study Highlights Endocannabinoid System’s Role in Muscle Health and CBD’s Therapeutic Potential
- The study highlights the crucial role of the endocannabinoid system, particularly the CB1 receptor, in skeletal muscle development and function.
- Disruptions in endocannabinoid signaling are linked to muscle-related conditions such as obesity, type 2 diabetes, sarcopenia, cachexia, and muscular dystrophies.
- CBD, a nonintoxicating cannabinoid, shows potential as a therapeutic agent for muscle disorders due to its effects on inflammation, metabolism, and cellular function pathways.
- While no new clinical trial data were presented, the review suggests targeting the endocannabinoid system could offer new treatments, emphasizing the need for further research on CBD’s impact on muscle health.
A new study published in the peer-reviewed journal Molecular Metabolism highlights the role of the endocannabinoid system in skeletal muscle health, while exploring CBD’s potential benefits for conditions affecting muscle function and metabolism.
Researchers from Université Clermont Auvergne examined how the endocannabinoid system, particularly the CB1 receptor, affects skeletal muscle development and function.
According to the researchers, disruptions in endocannabinoid signaling have been linked to several conditions involving skeletal muscle, including obesity, type 2 diabetes, sarcopenia, cachexia and muscular dystrophies. The review also explores emerging evidence surrounding cannabidiol, or CBD, a nonintoxicating cannabinoid found in marijuana and hemp. Researchers said CBD is drawing increased attention as a potential therapeutic option for conditions that affect skeletal muscle, due to its influence on pathways tied to inflammation, metabolism and cellular function.
Although the review does not present new clinical trial results, it provides an overview of current evidence suggesting that targeting the endocannabinoid system may offer new approaches for treating or managing muscle-related disorders.
Researchers concluded that further studies are needed to better understand how CBD and other cannabinoid-based interventions may influence skeletal muscle function in both healthy and disease states.
The study’s full abstract can be found below
The endocannabinoid (EC) system is a complex network comprising endogenous ligands, enzymes responsible for their synthesis and degradation, and various receptors (including CB1 and CB2). Present in many peripheral tissues, including skeletal muscle, EC system is now recognized to influence key physiological processes such as insulin sensitivity, mitochondrial metabolism, protein homeostasis and muscle development. Alterations in this system are associated with a variety of pathologies, including obesity, type 2 diabetes, sarcopenia, cachexia and muscle dystrophies. In this context, cannabidiol (CBD), a phytocannabinoid devoid of psychoactive properties, is attracting growing interest as a potential therapeutic agent. This article provides an analysis of the mechanisms by which the EC system, and more specifically the CB1 receptor, influences skeletal muscle development and function, while exploring emerging data on the potential benefits of CBD in various pathological conditions affecting skeletal muscle.